Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

Recursion Pharmaceuticals IncTrade
iShares 20 Plus Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Recursion Pharmaceuticals Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.26. Which is the better fit depends on your goals.

RXRXTLT
Market Cap
$1.81B
Sector
Health
52-Week High
$6.79$92.06
52-Week Low
$2.84$82.05
Enterprise Value
$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Recursion Pharmaceuticals Inc

RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.

Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.

iShares 20 Plus Year Treasury Bond ETF

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.40, up 0.43% on the day, amid a bearish technical signal with selling pressure dominating moving averages. Recent news highlights rising Treasury yields and inflation concerns, with institutional buying noted. The ETF provides exposure to long-term U.S. government bonds, with dividend distributions continuing regularly.

Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income but facing headwinds from potential Fed policy shifts. Key risks include yield volatility and macroeconomic factors impacting bond prices.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.

Read more on TLT